Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Myelodysplastic Syndromes 26Lymphoma, Non-Hodgkin 20Hematologic Neoplasms 20Lymphoma 19Multiple Myeloma 18Lymphoma, B-Cell 15Recurrence 14Lymphoma, Large B-Cell, Diffuse 13Leukemia, Lymphocytic, Chronic, B-Cell 12Burkitt Lymphoma 12Breast Neoplasms 11Pancreatic Neoplasms 10Lymphoma, Follicular 10Ovarian Neoplasms 9Melanoma 9Leukemia, Myelomonocytic, Chronic 9Neoplasm Metastasis 8Myeloproliferative Disorders 8Stomach Neoplasms 7Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 7Leukemia, Biphenotypic, Acute 7Leukemia 7Hodgkin Disease 7Glioblastoma 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 6

Interventions

fludarabine 1Positron-Emission Tomography 1Magnetic Resonance Imaging 1Cyclophosphamide 1Creatine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Muscle Weakness × fludarabine × Clear all
NCT06626919 2026-02-25

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Arcellx, Inc.

Phase 1 Recruiting
30 enrolled

Autoimmune Diseases, Muscular Diseases, Myasthenia Gravis, Muscle Weakness, Autoimmune Diseases of the Nervous System, Neuromuscular Manifestations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡